Mark Goldsmith, Revolution Medicines CEO (Mark Kauzlarich/Bloomberg via Getty Images)
December 8, 2022 07:16 AM EST
Deals

Sanofi walks away from $500M deal, leav­ing Rev­o­lu­tion alone in push­ing SHP2/KRAS com­bo

Amber Tong

In the four years since Sanofi teamed up with Rev­o­lu­tion Med­i­cines around its SHP2 in­hibitor — fronting a $500 mil­lion deal with $50 mil­lion in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times